G42 Healthcare, AstraZeneca agree to manufacture innovative drugs in Abu Dhabi

G42 Healthcare, AstraZeneca agree to manufacture innovative drugs in Abu Dhabi

G42 Healthcare, a UAE-based AI-powered healthcare company, and AstraZeneca, a science-led biopharmaceutical company, have signed a strategic partnership agreement to locally manufacture innovative drugs in Abu Dhabi.

The binding agreement focuses on collaboration in four key areas including localizing innovative industries, research and development, innovation and sustainability at a global scale. The agreement cements the emirate’s position as a hub for research and innovation in life sciences and is the latest in a series of longstanding partnerships with key players in the pharmaceutical industry.

The agreement is in line with the National Strategy for Industry and Advanced Technology and the Make it in the Emirates initiative, which was launched by the Ministry of Industry and Advanced Technology (MoIAT) to enhance the UAE’s business environment and position as an attractive destination for local and global industrial investors.

It also supports the growth and competitiveness of national industries, innovation and adoption of advanced technologies, and the UAE’s position as a global hub for future industries.

The binding agreement was signed by Mr. Ashish Koshy, Chief Executive Officer of G42 Healthcare and Ms. Pelin Incesu, Area Vice President, Middle East and Africa at AstraZeneca.

Ashish Koshy

CEO – G42 Healthcare “We are confident in the potential of our continuing